Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET190L1 ARTEMIS T Cells in CD19+ Non-Hodgkin's Lymphoma
NCT03379493Phase 1Terminated
- Sponsor
- Eureka Therapeutics, Inc.
- Start
- Apr 2018
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET019003 in Non-Hodgkin lymphoma (NHL), sponsored by Eureka Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 24 months and Toxicity profile of ET190L1 ARTEMIS T-cell treatment at 24 months. Started Apr 2018; status: terminated.
02
Drugs
ET019003
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03379493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03379493.